Alternative Translocation Breakpoint Cluster Region 5' to BCL-6 in B-cell

Non-Hodgkin’s Lymphoma by Butler, Marion P. et al.
[CANCER RESEARCH 62, 4089–4094, July 15, 2002]
Alternative Translocation Breakpoint Cluster Region 5 to BCL-6 in B-cell
Non-Hodgkin’s Lymphoma1
Marion P. Butler, Shinsuke Iida, Daniela Capello, Davide Rossi, Pulivarthi H. Rao, Palanisamy Nallasivam,
Diane C. Louie, Seeta Chaganti, Thomas Au, Randy D. Gascoyne, Gianluca Gaidano, Raju S. K. Chaganti, and
Riccardo Dalla-Favera2
Institute for Cancer Genetics, and the Departments of Pathology and Genetics & Development, Columbia University, New York, NY 10032 [M. P. B., S. I., R. D-F.]; Hematology
Unit, Division of Internal Medicine, Department of Medical Sciences, Amedeo Avogadro University of Eastern Piedmont, 28100 Novara, Italy [D. C., D. R., G. G.]; Cell Biology
and Genetics Programs, Memorial Sloan-Kettering Cancer Center, New York, New York 10021 [P. H. R., P. N., D. C. L., S. C., R. S. K. C.]; and the Department of Pathology,
British Columbia Cancer Agency, Vancouver, V5Z 4E6 Canada [T. A., R. D. G.]
ABSTRACT
Chromosomal translocations involving band 3q27 with various differ-
ent partner chromosomes represent a recurrent cytogenetic abnormality
in B-cell non-Hodgkin’s lymphoma. In a fraction of these translocations,
the chromosomal breakpoint is located within the 5 noncoding region of
the BCL-6 proto-oncogene where the BCL-6 major breakpoint region
(MBR) maps. As a result of the translocation, BCL-6 expression is dereg-
ulated by promoter substitution. However, between 30 and 50% of lym-
phomas with cytogenetically detectable translocations affecting band 3q27
retain a germ-line configuration at the BCL-6 locus. To identify possible
additional breakpoint clusters within 3q27, we cloned a t(3;14)(q27;q32)
lymphoma without MBR rearrangement and found a novel breakpoint
site located between 245 and 285 kb 5 to BCL-6. Breakpoints within this
newly described region, which we called the alternative breakpoint region
(ABR), were found to be recurrent in lymphomas carrying t(3q27) chro-
mosomal translocations but devoid of BCL-6 MBR rearrangements. Com-
parative analysis of multiple lymphomas carrying rearrangements within
the ABR showed that the breakpoints cluster within a 20-kb distance.
Translocations involving the ABR may juxtapose BCL-6 to distantly
acting, heterologous transcriptional regulatory elements which cause de-
regulation of the proto-oncogene. The identification of BCL-6 ABR pro-
vides new tools for the diagnosis of lymphomas carrying aberrations at
3q27 and deregulated BCL-6 genes.
INTRODUCTION
B-cell NHL3 form a heterogeneous group of neoplasms that arise as
a result of the clonal expansion of a single cell arrested at a specific
stage of B-cell differentiation (1). The uncovering of the genetic
elements involved in lymphomagenesis has been aided by cytogenetic
analysis, which has revealed that nonrandom chromosomal transloca-
tions are found in association with specific subtypes of NHL (1–2).
The molecular cloning of the breakpoint junctions of these transloca-
tions has led to the identification of several proto-oncogenes that
undergo transcriptional deregulation because of their juxtaposition to
regulatory elements of genes constitutively expressed in mature B
cells, most often represented by Ig genes (1). The B-cell NHL-
associated oncogenes discovered to date include BCL-1 at 11q13
involved in 95% of mantle cell lymphomas, BCL-2 at 18q21 in-
volved in 70–90% of FLs (1), c-MYC at 8q24, which is found to be
rearranged in 100% of Burkitt’s lymphoma (1), PAX-5 at 9p13 in-
volved in 50% of lymphoplasmacytoid lymphomas (1), and BCL-6 at
3q27 rearranged in 30–40% of DLBCLs and in 4–15% of FL cases
(3–5).
The BCL-6 gene encodes a nuclear phosphoprotein characterized
by six COOH-terminal Kruppel-type zinc finger motifs, and an NH2-
terminal POZ motif, shared by several zinc finger molecules, includ-
ing the Drosophila developmental regulators Tramtrak and Broad-
Complex, as well as the human KUP, ZID, and PLZF proteins (3).
BCL-6 has been shown to function as a potent transcriptional repres-
sor of promoters linked to its DNA target sequence (6–8). The BCL-6
protein is expressed in mature B-cells within germinal centers but not
in immature B-cell precursors or in differentiated plasma cells (9).
Targeted disruption of the BCL-6 gene shows that BCL-6 is essential
for germinal center formation, being involved in the control of Th2-
type immune responses (10, 11).
Rearrangements involving the BCL-6 gene at 3q27 cluster mainly
in a 4-kb genomic region, termed the MBR, which spans the first
noncoding exon of the gene (3–5). Translocations affecting band 3q27
in NHL are not limited to the Ig loci but may involve numerous
different partner chromosomes. The molecular characterization of
several 3q27 chromosomal translocations has shown that the coding
domain of the translocated BCL-6 gene becomes fused downstream to
heterologous promoters. These include the E and I promoters of Ig
genes in the case of t(3;14) as well as promoters of other genes,
namely TTF, BOB-1, H4, in the case of t(3;4), t(3;11), and t(3;6),
respectively (12–15). A general feature of promoters juxtaposed to
translocated BCL-6 is their constitutive expression in B-cells, which
leads to the inappropriate expression of BCL-6 (12–15).
Between 30 and 50% of the 3q27 chromosomal breakpoints found
in lymphomas do not occur within the MBR of BCL-6, suggesting the
presence of alternative breakpoints at 3q27 (3). To address this ques-
tion, we cloned a t(3;14)(q27;q32) occurring in a FL case shown to be
negative for rearrangement at the MBR of BCL-6. We detected a
novel breakpoint cluster located 245–285 kb upstream of the first
exon of the BCL-6 gene and termed ABR. This breakpoint site was
shown to be recurrent in several lymphomas with 3q27 chromosomal
translocations that lacked BCL-6 MBR rearrangement.
MATERIALS AND METHODS
Tumor Biopsies and Cell Lines. Lymph node biopsies from NHL cases
were obtained from the Memorial Sloan-Kettering Hospital. Tumors were
classified histologically according to the Revised European-American Lym-
phoma Classification (16). The t(3;14)(q27;q32)-positive NHL case 1952,
which served for BCL-6 ABR cloning, was diagnosed as having a FL dem-
onstrating an add (8)(q24) but no karyotypic evidence of a t(14;18)(q32;q21)
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translocation. Immunohistochemical analysis demonstrated that this tumor
expressed surface IgM.
Southern and Northern Blot Analysis. High molecular weight DNA was
extracted by the SDS/proteinase K method followed by “salting out” and
ethanol precipitation. Southern blot analysis was performed following standard
procedures. The following probes were used for Southern blot analysis of Ig
gene rearrangements: JH probe, represented by a 6.6-kb BamHI-HindIII frag-
ment from the IgH locus (17); and C probe, represented by a 1.3-kb EcoRI
fragment from the IgH locus (17). Some of the BCL-6 ABR probes used in this
study have been used in a previous study (18). For Northern blot analysis,
RNA was extracted from cell lines and patient samples using the guanidinium
thiocyanate/cesium chloride method, electrophoresed on a 1.0% agarose gel
containing 2.2 mM formaldehyde and transferred to a nylon membrane (Hy-
bond N; Stratagene).
Cloning of Chromosomal Breakpoints. High molecular weight DNA
from NHL case 1952 was digested with BamHI and size fractionated by
running on a 0.7% low-melting agarose gel. Fragments ranging from 12 to 23
kb were gel-purified and ligated into the Dash-II vector (Stratagene, La Jolla,
CA) and subsequently in vitro packaged using Gigapack III Gold packaging
extract (Stratagene, La Jolla, CA). Recombinant phage clones (1  106) were
screened by plaque hybridization using the JH and C Ig probes. Isolation of
germ-line 3q27 sequences was achieved by screening a human placenta library
(Stratagene) with probe 2.1 B/H derived from phage 1952–2 {corresponding
to der(14)} (Fig. 1).
Isolation of P1/PAC and YAC Clones and Construction of a 3q27
Contig. To establish a clone contig encompassing the BCL-6 gene, the Sac 4.0
probe (intron 1 of BCL-6) was used to screen a gridded P1 and PAC library
(Genome Systems, St. Louis, MO). P1 and PAC clone ends were isolated by
a vectorette-bubble PCR method and then used for genomic “walking” by
additional screening of P1 and PAC libraries (19). The single YAC clone
19GA10 described in the contig, isolated from the Zeneca (formerly ICI)
human YAC library, was obtained from the United Kingdom Human Genome
Mapping Project Resource Centre, Hinxton, United Kingdom. Confirmation
that the isolated P1 and PAC clones were from chromosome 3 was achieved
through the hybridization of PCR-derived end clone fragments to somatic cell
hybrid filters (panel 2, National Institute of General Medical Sciences Human
Genetic Mutant Cell Repository, Coriell Institute, Camden, NJ), as well as
FISH analysis to metaphase spreads of mitogen-stimulated normal human
lymphocytes. Insert sizing of P1 and PAC clones was achieved through their
digestion with NotI/SalI and NotI restriction digests, respectively. For YAC
clones, yeast cells were embedded in agarose plugs by a standard method and
analyzed by PFGE on the CHEF-DR II (Bio-Rad, Richmond, CA) after
restriction digestion.
FISH. Briefly, probes were labeled by nick translation with biotin-16-
dUTP or digoxigenin-11-dUTP and detected by indirect immunofluorescence
using fluorescein isothiocyanate-conjugated avidin and rhodamine-conjugated
anti-digoxigenin, respectively. Chromosomes were counterstained with 4,6-
diamidino-2-phenylindole. Images were captured with a cooled charge-
coupled device camera (Photometrics, Tucson AZ) attached to a Nikon
Microphot-SA microscope and processed using Smart capture imaging system
(Vysis, Downers Grove, IL).
DNA Sequencing. DNA sequencing was performed by the dideoxy chain
termination method using the ABI 373A automated sequencing system (Ap-
plied Biosystems, Foster City, CA).
RESULTS
Cloning of t(3;14) from a FL. Cloning of t(3;14)(q27;q32) was
performed on case 1952, represented by an IgM-producing FL. South-
ern blot analysis of Ig genes using BamHI and HindIII digestions and
probes for J, C, C, and C sequences showed the presence of three
rearranged J fragments, two of which did not comigrate with any
constant gene region probe (data not shown) as observed previously in
several cases of chromosomal translocations involving the IgH locus
(20). We then proceeded to clone the rearranged BamHI fragments
containing JH and C sequences from a recombinant phage library
constructed from BamHI-digested DNA from case 1952, which was
Fig. 1. Molecular characterization of the t(3;14) lymphoma case 1952. In A, the figure shows mapping of the recombinant phage clones 1952-23 and 1952-2, representing der(3)
and der(14) respectively, in addition to the normal germ-line phages 1952-15/11 at the BCL-6 ABR. Structural elements include the Ig enhancer element (E), as well as the switch
region (S) and coding segments (C and JH). Arrows indicate the position of the breakpoint in case 1952. Probes 2.1 B/H and 1.3 X are represented as thick horizontal lines and
were used to confirm chromosome 3 derivation by hybridization to somatic cell hybrid DNA filters. In B, the figure shows the nucleotide sequence analysis of the breakpoint junctions
of case 1952 and alignment to the corresponding germ-line regions. Sequence identities are indicated by the vertical lines. The sequences absent in der(3) and der(14), but present in
germ-line chromosome 3, are the result of a deletion during translocation. S motifs are underlined. Restriction enzyme abbreviations are: B, BamHI; E, EcoRI; H, HindIII; and
Bg, BgIII.
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screened by both JH and C probes. Restriction mapping and hybrid-
ization analysis revealed that the recombinant phage clones contained
JH and C sequences juxtaposed to sequences unrelated to the IgH
locus. To determine the chromosomal origin of these sequences, a
2.1-kb BamHI-HindIII fragment from 1952-2, as well as a 1.3-kb
XbaI fragment from 1952-23 (Fig. 1), were hybridized to DNA of
somatic-cell hybrids representative of individual human chromo-
somes. Both probes identified human sequences only on somatic cell
hybrids containing chromosome 3 (data not shown). Probe 2.1 B/H
from 1952-2 was then used to screen a genomic placenta library to
clone the corresponding normal locus on chromosome 3, represented
by phage clones 1952-15 and 1952-11 (Fig. 2).
Restriction mapping and partial sequence analysis of der(3) and
der(14) indicated that the clones represented a reciprocal translocation
(Fig. 1). The position of the breakpoints was mapped by sequencing
of derivatives (3) and (14) junctions regions, which revealed that the
recombination involved a deletion of 63 bp on chromosome 3 (Fig. 1).
FISH analysis of metaphase spreads prepared from case 1952 using
the phage contig (1952-15/11) as a probe revealed signals on chro-
mosomal derivatives (3) and (14) as well as normal chromosome 3,
band q27, thus confirming the derivation of these phages from a
t(3;14) (data not shown).
By sequencing analysis, the typical Ig switch pentameric repeat
motifs were seen in the immediate vicinity of the cloned breakpoint.
No apparent homology was detectable between chromosome 14 and
chromosome 3 sequences near the breakpoint.
Relationship between the 3q27 Breakpoint of Case 1952 and the
BCL-6 Gene. To define the position of the newly identified 3q27
breakpoint, a contig of P1, PAC, and YAC clones was constructed
linking the newly cloned ABR to the BCL-6 locus (Fig. 2). A
restriction map of the YAC clone 19GA10 is given in Fig. 2,
showing MluI and EagI restriction enzyme sites identified by
double enzyme digestion and by hybridization analysis using
YAC/PAC clone ends. By Southern blot hybridization analysis,
probe 1.3 X from ABR (Fig. 2) hybridized only to YAC clone
19GA10 in the contig. It hybridized specifically to a 220-kb MluI
restriction fragment of YAC clone 19GA10. An adjacent ABR
probe, termed 2.5 B/H, hybridized to a different MluI restriction
fragment of 85 kb (see Fig. 2). This indicates that the ABR is
located 220 kb from the left YAC arm terminus, 19GA10L. By
Southern blot hybridization analysis, probe 19GA10L hybridizes
to both P1371O8 and PAC133M19. The 5 marker of P1371O8 (T7
end) is positioned 65 kb 5 to exon 1 of BCL-6 by a combination
of PFGE and hybridization analysis (Fig. 2). Marker 133M19T7
maps 25 kb 5 to BCL-6 as determined by restriction fingerprint
analysis and hybridization analysis (data not shown). Overall,
these results indicate that ABR is positioned at a distance of
245–285 kb 5 to BCL-6.
Fig. 2. Physical map of the 3q27 genomic region encompassing the BCL-6 gene. The top panel shows a contig of P1, PAC, and YAC clones which covers a genomic region of
650 kb. The insert size of these reagents was determined by PFGE. The open circles represent nonchimeric clones as determined by hybridization of the PCR-derived end fragments
to somatic cell hybrid DNA panels. The extent of overlap between adjacent P1 and PAC clones was achieved through restriction fingerprint analysis. The BCL-6 gene is represented
as the filled box, exons 1 and 10 are indicated. The ABR is represented as a thick horizontal line (1952-15/11), the detailed schematic representation of which is shown in the bottom
panel. In the bottom panel, the black horizontal bars represent the probes used to assess for frequency of rearrangement at the ABR in the tumor cases. The fragment 2.5 B/H (s) was
used as a probe in Southern blot hybridization analysis to map the location of the ABR. The lymphoma cases positive for rearrangement at the ABR are indicated on the map, and
rearrangements are defined within HindIII restriction fragments. Restriction enzyme abbreviations are: B, BamHI; H, HindIII; Bg, BgIII; and E, EcoRI.
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Recurrency of the BCL-6 ABR in Lymphomas. To assess the
frequency of ABR, we collected a series of lymphomas (n  12)
with cytogenetic evidence of t(3q27) translocations but absence of
rearrangement involving the MBR of BCL-6. The histological and
partial cytogenetic profiles of these NHL cases are presented in
Table 1. Southern blots of HindIII-, BgIII-, and BamHI-digested
tumor DNAs were prepared and hybridized sequentially with
probes derived from phages 1952-15/11, exploring a genomic
distance of 40 kb surrounding the breakpoint of case 1952. All
rearrangements reported were confirmed by analysis with a second
enzyme digest. Representative results of hybridization analyses
with probes from the ABR on Southern blots of t(3q27) NHL cases
are shown in Fig. 3. Using probes 1.3 X and 0.4 HaeIII on HindIII,
BgIII, and BamHI Southern blot digests of lymphoma cases
(Fig. 3), rearrangements were seen in 42% (5 of 12) of NHL cases
that had cytogenetic evidence of t(3q27) chromosomal trans-
locations and that showed germ-line configuration of the MBR
(Table 1).
Subsequently, we investigated a cytogenetically uncharacterized
series of FL (n  20) and DLBCL (n  84) that were known to be
devoid of BCL-6 MBR rearrangements. Rearrangements of the BCL-6
ABR were detected in 10% (2 of 20) FL and 2.4% (2 of 84) DLBCL,
including one case arising in an immunocompetent host and one case
associated with AIDS. Mapping studies showed that all ABR rear-
rangements of BCL-6 clustered within a 20-kb region.
BCL-6 Expression Levels in NHL Cases with ABR Rearrange-
ment. To analyze the effect of ABR rearrangement on BCL-6 gene
expression, we examined the levels of BCL-6 expression in lym-
phoma cases 1952 (FL) and 1188 (DLBCL) (both rearranged at
ABR), as compared with two control FLs (cases 2065 and 1992)
showing no rearrangement at the ABR or MBR of BCL-6 (Fig. 4).
BCL-6 RNA levels were similar, independent of the BCL-6
genomic status. In addition, BCL-6 expression levels of case 1952
were also comparable with those of DLBCL cell line LY18 with
germ-line BCL-6, as well as of immunoblastic lymphoma LY8
carrying a MBR rearrangement. Overall, these results indicate that
Table 1 Rearrangement analysis at ABR in NHL cases with 3q27 chromosomal
translocations
Case Histology 3q27 aberration ABR MBR
1952 FL t(3;14)(q27;q32) R G
1562 DLBCL t(2;3)(q21;q27) R G
t(3;8)(q27;q13)
591 DLBCL t(3;22)(q27;q11) R G
95-625 DLBCL t(3;14)(q27;q32) R G
1188 DLBCL add(3q27) R G
498 DLBCL t(3;9)(q27;p13) G G
1187 FL t(2;3)(q21;q27) G G
770 DLBCL add(3q27) G G
1879 FL t(3;14)(q27;q32) G G
95-517 DLBCL t(2;3)(q12;q27) G G
95-89 DLBCL t(3;6;14)(q27;p35;q32) G G
91-153 DLBCL t(3;14)(q27;q32) G G
Fig. 3. Southern blots showing rearrangement at
the BCL-6 ABR in three representative lymphoma
cases. Rearrangements are depicted in lymphoma
cases 1188, 1562, and 95-625, confirmed by two
DNA digests.
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cases with ABR rearrangement express BCL-6 at levels compara-
ble with phenotypically similar cases with MBR rearrangement or
lacking 3q27 abnormalities.
DISCUSSION
B-cell NHL are typically characterized by recurrent chromosomal
translocations, which deregulate proto-oncogenes found at or in close
proximity to the chromosomal breakpoint junction areas (1). In some
translocations, exemplified by the BCL-1 and BCL-2 translocations,
the proto-oncogene may be involved by multiple, distinct breakpoint
clusters that are recurrent in different patients (21, 22). In the case of
3q27 translocations involving the BCL-6 proto-oncogene, only one
breakpoint cluster has been identified to date (3). This breakpoint
cluster, termed BCL-6 MBR, is detectable at the molecular level in
50–60% of lymphoma cases carrrying the 3q27 translocation (3–5).
The occurrence of lymphomas harboring 3q27 breaks but devoid of
BCL-6 MBR rearrangements point to the putative existence of other
BCL-6 breakpoint clusters. Here we report the identification of a novel
ABR, which, together with the BCL-6 MBR, accounts for 70% of
the total number of 3q27 chromosomal breakpoints detectable in NHL
cases.
The BCL-6 ABR is located at a distance of 280 kb telomeric to
BCL-6, raising the question of how the translocation induces BCL-6
deregulation. On the basis of the model of several other lymphoma
translocations, the ABR breaks may exert several possible modes of
BCL-6 deregulation. These include substitution of enhancer regions, a
mechanism which has been well demonstrated for many B-cell-
associated oncogenes, including BCL-1, BCL-2, c-MYC, PAX-5,
BCL-8, and BCL-9 (1). Enhancer substitution results from the inser-
tion of various IgH transcriptional control elements, such as the potent
JH-CH intron enhancer E, the 3E, or the 3-hs4, at the junction
region of the translocation breakpoint (23). An alternative mode of
BCL-6 deregulation by ABR translocations consists in the removal of
cis-acting regulatory domains in a fashion similar to that suggested for
some rearrangements involving the c-MYC locus (24). In the case of
NHL cases rearranged at the ABR but not involving the Ig genes, it is
conceivable that BCL-6 is deregulated by enhancer substitution of
genes other than Ig genes. Finally, it cannot be formally excluded that
ABR breaks affect genes mapping to 3q27 but unrelated to BCL-6.
However, the genomic region surrounding ABR analyzed to date
failed to reveal any functionally proven gene.
Our survey of BCL-6 ABR breakpoints in B-cell lymphoma defines
that the frequency of ABR rearrangements is substantially lower than
that of BCL-6 MBR. In fact, MBR rearrangements seem to be in-
volved in75% of DLBCL cases with cytogenetically detectable 327
breakpoints (3q27) (3), whereas ABR rearrangements account for
only a fraction (4 of 7, 50% in this study) of the remaining
MBR-negative 3q27 cases. Thus, ABR rearrangements are expected
to account for 12% of all 3q27 rearrangements, corresponding to an
expected frequency of 4% in the overall DLBCL populations and
consistent with the actual frequency observed in this initial study (2 of
84). Conversely, it is curious that the frequency of ABR rearrange-
ments in FL appears to be similar, or possibly higher, than that of
MBR rearrangements. Future studies on large panels of cases are
needed to define whether BCL-6 ABR rearrangements preferentially
associate with FL.
From a diagnostic standpoint, the results of this study point to the
need of long range DNA analysis for the correct identification of all
BCL-6 breakpoints occurring in lymphomas. In this respect, FISH
provides a powerful tool to detect both MBR and ABR BCL-6
breakpoints, thereby surpassing the capabilities of conventional
Southern blot hybridization analysis. In particular, highly predictive
analysis of BCL-6 rearrangements can be performed by FISH using as
a probe a 650-kb clone contig designed to detect breakpoints occur-
ring both at the MBR and ABR, as well as those which scatter around
the BCL-6 locus. Because a fraction of 3q27 breaks cannot be cur-
rently explained by BCL-6 breaks at MBR or ABR, FISH studies may
also lead to the discovery of additional BCL-6 breakpoint clusters that,
together with MBR and ABR, will recapitulate the molecular pathol-
ogy of 3q27 breaks in B-cell lymphoma.
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